No Data
Medrx Sees FY Loss Y1.35B
Medrx FY Loss Y806.00M Vs Loss Y932.00M
Medrx: Summary of Financial Results for the Fiscal Year Ending 2024/12 [Japanese GAAP] (Consolidated)
Kirin HD, Matsukiyo Cocok, Dentsu Group, Rakuten Group (14th) (1379-5368)
The above Calendar is merely a schedule and is subject to change due to the company's circumstances.--------------------------------------- February 14 (Friday) <1379> Hokuto <1380> Akigawa Boku-en <1417> Mirait-Wan <142A> Jinjibu <1438> Gifu Landscaping <1443> Giken HD <1447> SAAF HD <145A> Elizbee<
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause) of SAAFD. ＜3557＞ Large exercise of the 9th subscription rights (with exercise price adjustment clause) of U&C from the 4th, number of shares delivered, 0.07 million, 2000 shares. ＜4576＞ Approval obtained in Thailand for the glaucoma and ocular hypertension treatment "Grau Alpha combination eye drops (domestic product name)" of DWTI. ＜4586＞ Termination of joint research contract with Medrec Fanpepp. ＜4881＞ Soleasia's downward revision, current period operations.
Medrx Sees FY Loss Y846.00M